Norepinephrine and gamma‐aminobutyric acid in amyotrophic lateral sclerosis

Abstract
Patients with amyotrophic lateral sclerosis have increased levels of the neurotransmitter norepinephrine in blood and cerebrospinal fluid and depressed levels of the inhibitory neurotransmitter gamma-aminobutyric acid in cerebrospinal fluid. These neurochemical alterations are most marked in patients bedridden with advanced disease, appear interrelated, and lead to cardiovascular alterations in patients with amyotrophic lateral sclerosis.